Journals / Eurasian Journal of Medicine / 2020 / Cilt: 52 - Sayı: 2

Comparison of Functional Capacity and Symptoms of COPD Patients with and without Pulmonary Hypertension

Pages
166–170
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Using CPET in the functional evaluation of patients with COPD may be beneficial in the early detection of PH.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Pulmonary hypertension (PH) is a common complication of chronic obstructive pulmonary disease (COPD) associated with a decrease in the survival rate of patients with COPD.
📊
Key Findings & Data:In addition, we aimed to evaluate the correlation between the functional capacity and symptoms score in patients with COPD.Materials and Methods: This prospective cross-sectional study enrolled 64 patients with moderate to severe COPD, prospectively.
💡
Conclusion & Impact:Using CPET in the functional evaluation of patients with COPD may be beneficial in the early detection of PH.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Pulmonary hypertension (PH) is a common complication of chronic obstructive pulmonary disease (COPD) associated with a decrease in the survival rate of patients with COPD. Our aim was to investigate whether PH impairs the functional capacity and symptoms in patients with COPD. In addition, we aimed to evaluate the correlation between the functional capacity and symptoms score in patients with COPD.Materials and Methods: This prospective cross-sectional study enrolled 64 patients with moderate to severe COPD, prospectively. All patients underwent the pulmonary function test, echocardiography, 6-minute walk test (6MWT), and cardiopulmonary exercise testing (CPET). We applied the modified Medical Research Council (mMRC) dyspnea scale and COPD Assessment Test (CAT) to all patients. The mean pulmonary arterial pressure (mPAP) >30 mmHg with echocardiography was considered as PH. The patients were grouped according to the presence of PH as COPD-PH (n=30) and COPD-nonPH (n=34).Results: Hospitalization rate was higher in the COPD-PH group than in the COPD-nonPH group (p=0.006). The 6MWT results were lower in the COPD-PH group compared to the COPD-nonPH group (325±61 m vs. 354±46 m, respectively, p=0.025). In the COPD-PH group, the maximum oxygen consumption (VO2max) was lower, but the difference did not reach statistical significance (p=0.118). Although the maximum load and minute ventilation were lower in the COPD-PH group, the end-tidal pressure of CO2 (PETCO2) was higher (p=0.033, p=0.036, and p=0.009, respectively). However, the CAT score and mMRC were similar between the groups (p=0.405 and p=0.238, respectively).Conclusion: An elevated PAP in patients with COPD limits the exercise capacity. Using CPET in the functional evaluation of patients with COPD may be beneficial in the early detection of PH.

🔖

Cite This Article

ARAZ, Ö., KALKAN, K., UÇAR, E. Y., KALKAN, F. (2022). Comparison of Functional Capacity and Symptoms of COPD Patients with and without Pulmonary Hypertension. Eurasian Journal of Medicine, Cilt: 52 - Sayı: 2, 166–170. https://ajindex.com/articles/508911

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2015. Available from: URL: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2015/.2015 Accessed August 20
  2. World Health Organization [webpage on the Internet] Global Health ObservatoryDataRepository2016. Available from: URL: http://apps.who.int/gho/data/node.main.CODWORLD?lang=en. 2016 Accessed August 20
  3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349: 1498-504. [Crossref] 4. Bishop JM. Hypoxia and pulmonary hypertension in chronic bronchitis. Prog Respir Dis 1975; 9: 10-6. [Crossref] 5. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-94. [Crossref] 6. Weitzenblum E, Sautegeau A, Ehrhart M, et al. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130: 993-8
  4. Scharf SM, Iqbal M, Keller C, et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166: 314-22. [Crossref] 8. Fishman A. Hypoxia on the pulmonary circulation. How and where it acts. Circulation 1976; 38: 221-31. [Crossref] 9. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 2005; 60: 605-9. [Crossref] 10. Scharf SM, Iqbal M, Keller C, et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166: 314-22. [Crossref] 11. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531-6. [Crossref] 12. Blanco I, Pıccarı L, Barberà JA. Pulmonary vasculature in COPD: The silent component. Respirology 2016; 21: 984-94. [Crossref] 13. Ozdemirel TS, Ulaşli SS, Yetiş B, et al. Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD: an observational study. Anadolu Kardiyol Derg 2014 Jun; 14: 370-7. [Crossref] 14. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-38. [Crossref] 15. Quanjer PH, Tammeling GJ, Cotes